Luciole Medical

What Luciole Medical does

Luciole Medical AG is a Swiss medical technology company founded in 2007 and headquartered in Zurich, Switzerland, that develops near-infrared spectroscopy (NIR) based systems for real-time monitoring of cerebral oxygenation, blood flow, intracranial pressure, and brain temperature. The company's integrated platform comprises three CE-marked products: RheoPatch, a non-invasive adhesive sensor that measures brain tissue oxygen metabolism and blood flow; RheoSens, a sterile, single-use intracranial probe placed in brain tissue for up to eight days; and RheoLity, an analytics software platform that aggregates and visualizes sensor data on standard medical PCs. Luciole holds both CE certification and EU MDR (2017/745) approval for the patch-probe combination, which it states is unique in the market, and its technology is protected by a portfolio of granted European and US patents, including a patented method for measuring cerebral blood flow adapted from validated heart-analysis techniques.

The company serves clinical use cases across anesthesia and surgery (cardiac, orthopedic/spine, ECMO), neurocritical care (subarachnoid hemorrhage, traumatic brain injury, severe stroke, cardiac arrest), pediatric care, and sleep apnea. In June 2023, Luciole acquired German catheter and EVD kit provider Spiegelberg GmbH & Co. KG, which distributes intracranial pressure measurement and cerebrospinal fluid drainage products in more than sixty countries, materially expanding the company's neurocritical care portfolio and global distribution footprint.

Luciole generates revenue primarily through hardware sales of disposable probes and multi-use patches, alongside a software component via the RheoLity analytics platform, sold into hospitals and clinical facilities through enterprise field sales. The company is privately held, has 11–50 employees, has disclosed one funding round of $5.5M in September 2018, and has stated it is actively seeking additional investment to accelerate development. No current revenue figures are publicly disclosed.

Name

Luciole Medical

Legal name

Luciole Medical AG

Website

https://luciolemedical.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Luciole Medical AG is a Swiss medtech company developing CE-marked near-infrared spectroscopy brain monitoring systems (RheoPatch, RheoSens, RheoLity) for real-time cerebral oxygenation, blood flow, and intracranial pressure monitoring in hospital surgery, neurocritical care, and pediatric settings.

Ownership category

akta.pro rank

Product category

Brain Monitoring Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

Keywords

• Brain monitoring devices
• Cerebral oxygenation monitoring
• Intracranial pressure measurement
• Near-infrared spectroscopy
• Neurocritical care devices

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of hardware medical devices including invasive intracranial probes (RheoSens) and non-invasive adhesive patches (RheoPatch). Probes are disposable single-use products; patches are multiple-use sensors.
2. Software Platform: RheoLity software analytics platform sold in conjunction with hardware sensors for data analysis and patient information management.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Luciole Medical develops and manufactures brain oxygenation monitoring devices based on near-infrared spectroscopy, including the non-invasive RheoPatch adhesive sensor, the invasive single-use RheoSens intracranial probe, and the RheoLity analytics software platform. Products provide real-time monitoring of cerebral oxygenation, blood flow, intracranial pressure, and brain temperature for use during cardiac, orthopedic, and spine surgeries, neurocritical care, ECMO, and pediatric procedures in hospitals and clinical settings.

Product overview

Luciole Medical offers a unified brain monitoring platform consisting of three core products: the non-invasive RheoPatch adhesive sensor, the intracranial RheoSens probe, and the RheoLity analytics software platform. The patch and probe sensors feed real-time cerebral oxygenation, blood flow, intracranial pressure, and temperature data into the RheoLity monitoring platform for display and patient data management. Additionally, the company acquired Spiegelberg GmbH & Co. KG, which expands the portfolio with intracranial pressure measurement and cerebrospinal fluid drainage products.

Differentiator

Problem solved

Functional benefit

Brands

• RheoPatch: Adhesive non-invasive multiple-use sensor that measures oxygen metabolism and blood flow of subjacent brain tissue. CE certified.
• RheoSens
• RheoLity

Products and services

• RheoPatch Non-invasive adhesive sensor that measures oxygen metabolism and blood flow of subjacent brain tissue. Can be used standalone or in parallel with the RheoSens probe for comprehensive brain hemodynamic monitoring. CE certified.
• RheoSens Sterile implantable intracranial probe that measures intracranial pressure (ICP), brain temperature, oxygen metabolism, and cerebral blood flow. Disposable single-use device for placement in brain tissue for up to 8 days, used for patients with severe brain injuries. CE certified.
• RheoLity Analytics software platform that analyzes cerebral blood flow and instant oxygen metabolism data captured by RheoPatch and RheoSens sensors, displaying data on a standard medical PC in an intuitive format. Manages patient information and measurements. CE certified.
• Spiegelberg intracranial pressure and cerebrospinal fluid drainage products Acquired product line from Spiegelberg GmbH & Co. KG, including intracranial pressure measurement devices, cerebrospinal fluid drainage products (external ventricular drains and kits for neurosurgery), and intra-abdominal pressure (IAP) measurement devices. Distributed in over sixty countries as part of Luciole's combined neurocritical care portfolio.

Quantifiable outcome

• Probe can be placed in brain for up to 8 days
• +1 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Spiegelberg GmbH & Co. KGcoreStrategic or Co-development Partner · 27 June 2023In June 2023, Luciole Medical AG acquired German catheter and EVD kit provider Spiegelberg GmbH & Co. KG to strengthen its neurocritical care portfolio. Spiegelberg develops, produces and distributes products for intracranial pressure measurement, cerebrospinal fluid drainage and IAP measurement in more than sixty countries. The acquisition combined product lines and distribution channels, with the goal of becoming a global leader in next-generation brain monitoring devices. Manufacturing and distribution channels were combined to optimize strengths.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Masimo: Global patient monitoring leader offering cerebral/somatic oximetry (O3 Regional Oximetry) using multi-wavelength NIRS. Direct competitor in hospital-based brain oxygenation monitoring with broad ICU and OR footprint.
• Nonin Medical: Manufactures regional cerebral oximetry sensors (SenSmart) and pulse oximetry devices. Direct competitor in NIRS-based cerebral and tissue oxygenation monitoring across hospital and clinical settings.
• Ornim Medical: Developed the c-FLOW and CerOx NIRS/US-based cerebral blood flow and oxygenation monitors for perioperative and ICU use. Direct competitor in cerebral blood flow measurement, overlapping with Luciole's patented ICG-based CBF approach.
• Edwards Lifesciences (ForeSight, via CAS Medical): Acquired CAS Medical Systems, whose ForeSight is a leading cerebral oximeter using NIRS for non-invasive brain oxygenation in cardiac and major non-cardiac surgery. Direct competitor in the same product category and customer base.
• Medtronic (INVOS Cerebral Oximetry): Acquired Covidien's INVOS system, the most established near-infrared spectroscopy-based regional cerebral oximetry platform used in cardiac surgery and ICUs. Direct competitor to RheoPatch/RheoSens in brain oxygenation monitoring with a much larger global commercial footprint.

Broad incumbents

• Integra LifeSciences: Broad neurosurgery and neurocritical care portfolio including ICP monitors, EVDs, and cranial access devices. Overlaps with Spiegelberg's ICP/EVD business and competes for the same neurosurgical hospital buyers.
• Drägerwerk: Major ICU and OR monitoring and ventilation player with patient monitoring platforms that integrate cerebral and hemodynamic parameters. Broad incumbent competing in hospital monitoring procurement alongside cerebral oximetry vendors.

Others

• Spiegelberg GmbH & Co. KG: Now a wholly-owned subsidiary of Luciole Medical, but historically an independent peer offering intracranial pressure monitors, EVDs, and CSF drainage products. Comparable for legacy ICP and neurosurgical device portfolio that drove the acquisition.

Emerging players

• NIRx Medizintechnik: Specialized fNIRS brain imaging company serving neuroscience research markets. Adjacent competitor using similar NIR spectroscopy technology, with partial overlap in optical brain monitoring use cases.
• Hitachi Medical (ETG fNIRS systems): Offers the ETG series of functional near-infrared spectroscopy (fNIRS) systems for brain function imaging in research and clinical neurology. Comparable optical/NIRS brain monitoring technology but historically focused on functional imaging rather than oxygenation metrics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/luciolemedical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luciole Medical